US Series A Weekly Funding Roundup (Apr 18-25, 2026): $33.5M Raised Across 2 Deals

Table of Contents

US Series A activity slowed to two deals worth $33.5M between April 18 and 25, 2026, a quieter week shaped by capital concentrating at the extremes. Earlier-stage startups absorbed most of the action, with US seed companies pulling in $136.3M across eight rounds, while two late-stage US deals closed a combined $125.0M. The Series A middle felt the squeeze.

The two rounds that did close hit very different sectors. Monk took the larger check for AI-driven accounts receivable automation, an enterprise-software play with a clear working-capital pitch. Omeza closed a smaller round for FDA-cleared regenerative wound care, a commercial-stage healthtech bet. Together they reflect what’s still drawing Series A money in 2026: agentic AI applied to back-office finance, and clinical products with regulatory clearance already in hand.

1. Monk Raises $25M For AI-Native Accounts Receivable

Deal Overview

• Stage: Series A
• Sector: AI / Fintech (accounts receivable automation)
• Geography: New York City, United States
• Round size: $25M (total raised: $29M)
• Lead investors: Footwork and Acrew Capital, with continued participation from BTV

Investor Profile

Footwork and Acrew Capital co-led the round, both known for early bets on AI-applied vertical software. BTV’s continued participation signals conviction from an earlier backer who has watched the metrics up close.

The investor mix matters here. Footwork tends to back companies where AI changes unit economics rather than just the demo. Acrew has built a portfolio around fintech infrastructure, and AR sits squarely in that lane.

Company and Leadership

Monk was co-founded by George Kurdin and Joe Zhou. Kurdin’s background spans D.E. Shaw, Mojang/Minecraft, and Streamlabs, an unusual mix of quantitative finance and consumer-scale product. Zhou came out of engineering roles at Google and Snap.

The team is based in New York and announced the round on April 21, 2026.

Problem and Opportunity

B2B accounts receivable still runs on spreadsheets, ERP-bolted modules, and manual chasing. Outstanding US B2B receivables sit above $3T at any given time, and every day of delay drags on working capital.

Finance teams at SMB and mid-market companies feel this most. They lack the headcount to run sophisticated dunning workflows but carry the same cash-flow exposure as larger peers.

Product and Technology

Monk runs the full AR workflow with AI agents: invoice generation and delivery, dunning sequences, payment reconciliation, and collections follow-up. Customers report a 40% drop in days sales outstanding, 25+ hours saved per AR team each month, and a 24% lift in collections response rates.

The data edge compounds with usage. Monk accumulates payment-behavior data, dunning-effectiveness signals, and channel-specific response rates across deployments. Continuous A/B testing on messaging cadence feeds back into agent decision policies, so each new customer makes the system slightly better for the next.

Use of Proceeds and Vision

The $25M will go toward R&D as Monk builds out adjacent products in the accounts receivable stack. The framing positions AR as a strategic cash-flow lever, not back-office paperwork.

Long-term, the team is aiming at autonomous AR that closes the cash-conversion-cycle gap for B2B businesses end-to-end.

Market Context

AR/AP automation has attracted a wave of AI-native entrants in 2025 and 2026. Peers include Tabs, Tesorio, Centime, and Versapay, with HighRadius as the incumbent. The category is competitive, but the scale of stuck working capital and measurable ROI from automated collections give the winners room to grow.

Case Studies

Startups like yours already closed their rounds with us.

Founders across every stage and industry. Here's what it took.

• Raised $7.6M for Swiipr Technologies
• Raised $0.5M for Ap Tack
• Raised €0.5M for Ivent Pro

Read their stories →

2. Omeza Raises $8.5M For Advanced Wound Care

Deal Overview

• Stage: Series A
• Sector: Healthtech (advanced wound care)
• Geography: Sarasota, Florida, United States
• Round size: $8.5M
• Investors: Astanor, BluKap Ventures, Catalyst Investments, Florida Opportunity Fund

Investor Profile

The syndicate blends agri-food and life-sciences investor Astanor with regional players including BluKap Ventures, Catalyst Investments, and Florida Opportunity Fund. The state-linked Florida Opportunity Fund’s involvement reflects local interest in keeping a Sarasota-based commercial-stage company well capitalized.

The investor profile fits a commercial-stage healthtech round: a mix of strategic and regional capital backing a company that already has FDA clearance and revenue rather than betting on early science risk.

Company and Leadership

Omeza Holdings is a commercial-stage advanced wound care company headquartered in Sarasota, Florida. Its lead product is FDA-cleared and already on the market.

That commercial-stage status changes the risk profile compared with most healthtech Series A rounds, which often fund clinical trials rather than scaling sales.

Problem and Opportunity

Chronic and complex wounds are a costly problem in US healthcare, particularly among diabetic and elderly patients. Standard-of-care options often fall short for hard-to-heal wounds, leaving clinicians and patients with limited choices.

Regenerative wound care products that hold FDA clearance can plug into existing wound clinic workflows and reimbursement pathways, which lowers adoption friction.

Product and Technology

Omeza markets an FDA-cleared regenerative wound care product. The clearance gives it a defensible position against early-stage competitors still working through regulatory pathways.

For commercial-stage healthtech at this round size, the focus typically shifts from product validation to scaling field sales, building clinician relationships, and securing favorable payer coverage.

Use of Proceeds and Vision

An $8.5M Series A at commercial stage usually funds sales-team expansion, clinical evidence generation to support payer conversations, and modest manufacturing scale-up.

The vision is to grow share within advanced wound care by leaning on the regulatory head start.

Market Context

The US advanced wound care market is multi-billion-dollar and growing as the diabetic and aging populations expand. It’s a fragmented competitive field with established players like Organogenesis, MiMedx, and Smith+Nephew. Clinical evidence and reimbursement coverage are the gating factors for new entrants, so an FDA-cleared product backed by fresh capital has a real path to share gains.

Lessons For Founders

• Series A rounds in 2026 are concentrating around AI-applied vertical software with measurable ROI. Monk’s pitch leads with hard numbers (40% DSO reduction, 25+ hours saved monthly), not capability claims.
• Founder pedigree still moves checks. Kurdin’s mix of quant finance and consumer product, paired with a Google/Snap engineering co-founder, made the AR thesis credible to AI-fintech investors.
• Regulatory clearance is the moat for healthtech Series A rounds. Omeza’s FDA-cleared product let it raise on commercialization economics, not clinical-trial risk.
• Data advantages that compound with usage are now table stakes for AI Series A pitches. Monk’s per-deployment learning loop on payment behavior and dunning effectiveness is the kind of moat investors want to see articulated.
• Regional and strategic investors matter for commercial-stage healthtech. Omeza’s syndicate mixes sector specialists with state-linked capital, a useful template for founders outside the coastal hubs.